Wuhan HealthCare Biotechnology Co., Ltd. is located in Wuhan Optics Valley Bio-Lake, National Bio-Industry Base was founded on the Feb. 19, 2013. The company is a high-tech enterprise integrating R&D, production, sales and testing services with the strategic direction of precise medical diagnosis products for major diseases such as cancer, cardiovascular and cerebrovascular diseases.

Since its inception, the company has been committed to providing more efficient diagnostic products, with emphasis on independent research and development, and has established multi-disciplinary R&D teams in Clinical Medicine, Molecular Biology, Microfluidics, Mechanical Automation and other disciplines. The company has more than 10 invention patents and its torchbearer FastProbe® fluorescence in situ hybridization probe preparation technology with full independent intellectual property rights is at the international front level. Based on this patented technology, the new generation of probe hybridization incubation time is only 2 hours, shortening the fluorescence in situ hybridization detection time from 3 days to a few hours, with higher sensitivity, specificity and bright signal to noise ratio.

At the same time, the company has built a complete domestic and international marketing system and FastProbe® has entered more than 20 countries, and regions oversea, won a good market reputation and wide customer recognition, and become a leading brand of fast fluorescence in situ hybridization probe in the world.

Adhering to the tenet of “Fastness, Precision, and Beyond Expectation”, the company has been working tirelessly to contribute to the development of precision medical care worldwide.